Phase II Study of Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery for Patients With Localized, Resectable, Adenocarcinoma of the Pancreas
Phase of Trial: Phase 0
Latest Information Update: 10 Mar 2016
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 06 Nov 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 09 Nov 2013 Planned number of patients changed from 30 to 12 as reported by ClinicalTrials.gov.
- 11 Feb 2013 New trial record